Drug intelligence / Profile preview

wortmannin

Development stage
Preclinical
Modality
Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
Administration
Intraperitoneal (experimental/research Use)
01

Overview

Wortmannin is a steroidal metabolite produced by the fungi Penicillium funiculosum and Talaromyces wortmannii. It is a potent, covalent, and irreversible inhibitor of phosphoinositide 3-kinases (PI3Ks), acting on class I, II, and III PI3K isoforms at nanomolar concentrations. Wortmannin also inhibits other kinases at higher concentrations, including DNA-dependent protein kinase (DNA-PK), ataxia telangiectasia mutated kinase (ATM), myosin light chain kinase (MLCK), ATR kinase, and members of the polo-like kinase family such as PLK1 and PLK3. Its mechanism involves covalent modification of lysine residues in the ATP-binding site of these kinases. Wortmannin has been widely used as a research tool to study cell signaling pathways involving PI3Ks, autophagy inhibition, DNA repair inhibition, cell proliferation suppression, receptor-mediated endocytosis blockade, and induction of apoptosis or cell death in various models. It exhibits antiproliferative activity in vitro but is not approved for clinical use due to instability in biological fluids and toxicity concerns[1][2][3][5][6].

Other names
wartmannin
02

Targets

ATM (Ataxia telangiectasia mutated protein)DNA-PK (DNA-dependent protein kinase)PLK1 (Polo like kinase 1)PLK3DNAPI3K (Phosphoinositide-3-kinase regulatory subunit 6)MLCK (Myosin light chain kinase)ATR (ATR serine/threonine kinase)

Beyond the preview

Go deeper on wortmannin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on wortmannin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call